Core Viewpoint - Silo Pharma, Inc. has announced a partnership with Sever Pharma Solutions to scale up the production of its SP-26 ketamine-based injectable implant aimed at treating chronic pain and fibromyalgia, with ongoing analytical testing to optimize the formulation [1][2]. Company Overview - Silo Pharma is a developmental stage biopharmaceutical company focused on creating novel therapeutics for underserved conditions, including chronic pain and psychiatric disorders [4]. - The company's lead program, SPC-15, targets PTSD and stress-induced anxiety, while SP-26 is designed as a time-release ketamine implant for chronic pain relief [4]. Product Details - SP-26 is a ketamine-based injectable dissolvable polymer implant that aims to safely regulate dosage and time release for pain relief [3]. - The implant is currently undergoing pre-clinical studies to finalize its dosage and formulation, with the potential to qualify for the FDA's streamlined 505(b)(2) regulatory pathway if clinically successful [2]. Collaboration and Development - The collaboration with Sever Pharma Solutions builds on previous successful production and validation of the ketamine implants, indicating a strong partnership in advancing the product [2]. - The ongoing analytical testing will help in selecting the optimal final dosage and formulation for animal studies [2].
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic